Posts

Posted on

Northern Trust Supports Launch of Europe’s First Autocallable ETF on Waystone’s ETF ICAV platform

Northern Trust Supports Launch of Europe’s First Autocallable ETF on Waystone’s ETF ICAV platform

ETF Servicing Solutions Support Launch of Calamos Investments’ Strategy for European Investors

DUBLIN–(BUSINESS WIRE)–
Northern Trust (Nasdaq: NTRS) today announced it has supported the launch of a new exchange‑traded fund (ETF) on the Waystone ETF ICAV, Waystone’s Irish‑domiciled white‑label multi‑manager ETF platform.

The launch of the Calamos Autocallable Income UCITS sub fund introduces U.S. asset manager Calamos Investments (Calamos) onto the platform and marks the first autocallable ETF in Europe.1 Calamos is headquartered in Naperville, Illinois, and has $47.2 billion in assets under management (as of 31 March 2026).

This derivatives‑based, synthetic investment strategy seeks to deliver returns that reflect the performance of a benchmark index designed to track a diversified portfolio of synthetic autocallable notes. The strategy provides equity-linked exposure with the potential for regular coupon income while incorporating predefined downside thresholds. Autocallables are market-linked investments which offer regular coupons and return principal at maturity, contingent on the performance of an underlying equity index.

Waystone is a leading asset-servicing solutions provider of institutional governance, administration, risk and compliance services to the global asset management industry. The new fund, listed on the Xetra and London Stock Exchanges, is being supported through Northern Trust’s servicing relationship with the Waystone ETF ICAV – to which it provides fund administration, depositary and custody services. This relationship has provided Calamos with an established and efficient route to market in Europe.

“We congratulate Calamos and Waystone on the launch of this new fund and are delighted to have supported its speed-to-market within the UCITS framework,” said Melíosa O’Caoimh, Ireland Country Head, Northern Trust. “Our ETF servicing capabilities and technology support the full lifecycle of products and fund structures – helping managers bring innovation to market, to efficiently scale and operate their funds, and capitalize on growing industry-wide interest in use of these products to reach investors.”

Paul Heffernan, CEO of Waystone ETFs, said: “Partnering with Calamos and Northern Trust on the first UCITS autocallable fund is a strong example of how managers are approaching growth today. Through our white label ETF platform, we enable firms to bring innovative strategies to market efficiently while expanding into new regions with the right governance, ETF capital markets, operating model and distribution in place. The ability to list widely across Europe and Latin America from launch highlights how important it is to have the right infrastructure behind you. As demand for more sophisticated, globally distributed products continues to grow, this is exactly where we support our clients.”

Northern Trust’s Global Fund Services provides a complete suite of asset servicing solutions including fund administration, global custody, investment operations outsourcing and data solutions – supporting a range of complex investment strategies across the full spectrum of asset classes.

1Autocallable ETF lined up by Calamos in Europe first

About Northern Trust

Northern Trust Corporation (Nasdaq: NTRS) is a leading provider of wealth management, asset servicing, asset management and banking services to corporations, institutions, affluent families and individuals. Founded in Chicago in 1889, Northern Trust has a global presence with offices in 24 U.S. states and Washington, D.C., and across 22 locations in Canada, Europe, the Middle East and the Asia-Pacific region. As of March 31, 2026, Northern Trust had assets under custody/administration of US$18.6 trillion, and assets under management of US$1.8 trillion. For more than 135 years, Northern Trust has earned distinction as an industry leader for exceptional service, financial expertise, integrity and innovation. Visit us on northerntrust.com. Follow us on Instagram @northerntrustcompany or Northern Trust on LinkedIn.

Northern Trust Corporation, Head Office: 50 South La Salle Street, Chicago, Illinois 60603 U.S.A., incorporated with limited liability in the U.S. Global legal and regulatory information can be found at https://www.northerntrust.com/terms-and-conditions.

Media Contacts

Europe, Middle East, Africa & Asia-Pacific:

Camilla Greene

+44 (0) 20 7982 2176

[email protected]

Simon Ansell

+ 44 (0) 20 7982 1016

[email protected]

US & Canada:

John O’Connell

+1 312 444 2388

John_O’[email protected]

KEYWORDS: Europe Ireland United Kingdom

INDUSTRY KEYWORDS: Personal Finance Finance Banking Professional Services Asset Management

MEDIA:

Logo
Logo
Posted on

Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease

  • The Boards of Directors of Angelini Pharma and Catalyst Pharmaceuticals have unanimously approved the acquisition of Catalyst Pharmaceuticals at 31.50 USD per share in cash, for a total consideration of approximately 4.1 billion USD, representing a premium of 28% to the 30-day volume-weighted average trading price as of April 22, 2026
  • The transaction marks Angelini Pharma’s entry into the U.S. market, reinforcing its long-term commitment to Brain Health and its dedication to people living with Rare Diseases
  • Closing is expected in the third quarter of 2026

An earlier release was issued which has now been corrected.

ROME and CORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) — Angelini Pharma S.p.A. (“Angelini Pharma”), an international pharmaceutical company and part of the Angelini Industries Group, and Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that they have entered into a definitive agreement pursuant to which Angelini Pharma has agreed to acquire all outstanding shares of Catalystfor 31.50 USD per share in cash, for a total equity value of approximately 4.1 billion USD (equivalent to 3.5 billion euros) which represents a 21% premium to Catalyst’s unaffected closing share price on April 22, 2026, the last trading day before market signs that the transaction had become public information, as well as a 28% premium to the 30-day volume-weighted average trading price to that unaffected date. The transaction has been unanimously approved by the Boards of Directors of both companies and is expected to close in the third quarter of 2026.

This acquisition marks a pivotal moment in the Angelini Group’s history — a group with over 100 years of history, chaired by Thea Paola Angelini, a fourth-generation member of the Angelini family — led by Sergio Marullo di Condojanni, Chief Executive Officer of Angelini Pharma.

The transaction will be carried out with the participation of Blackstone funds and select international partners, and will be financed with the support of BNP Paribas, acting as Sole Global Coordinator and Underwriter of the financing package.

Founded in 2002 and listed on Nasdaq since 2006, Catalyst has built a robust portfolio of products focused on the treatment of rare neuromuscular and neurological diseases: FIRDAPSE® (amifampridine), the only evidence-based treatment approved by the U.S. Food and Drug Administration (FDA) for Lambert-Eaton myasthenic syndrome (LEMS) in patients aged six and above; AGAMREE® (vamorolone) a novel corticosteroid approved by the FDA in 2023 for the treatment of Duchenne Muscular Dystrophy (DMD) in patients aged 2 and above; and FYCOMPA® (perampanel), an antiepileptic drug approved for the treatment of partial-onset seizures and primary generalised tonic-clonic seizures, the U.S. rights to which were acquired from Eisai in 2023.

Following completion of the acquisition, Angelini Pharma intends to integrate Catalyst’s portfolio and exceptional commercial infrastructure with its own expertise and products in Brain Health to develop a next-generation therapeutic platform in Rare Diseases. This transaction reinforces the commitment Angelini Pharma has built over recent years through products such as Ontozry® and high-profile scientific collaborations. Catalyst’s portfolio is expected to significantly strengthen the company’s strategic objectives, growing its presence in the U.S. as part of a balanced strategy that aims to develop the North American market while continuing to strengthen its core business in Europe. Angelini Pharma’s continued industrial presence in Italy will remain a strategic asset as a valuable production and scientific center within the combined company’s global operations.

Sergio Marullo di Condojanni, CEO of Angelini Pharma, commented: “Five years ago, we embarked on a profound transformation of Angelini Pharma — organizational, scientific and strategic — with the ambition to build a company capable of competing at the highest global level. On one hand, we continued to invest in our traditional portfolio; on the other, we chose to focus on central nervous system disorders, with the goal of addressing an unmet medical need that is, unfortunately, growing significantly. We invested in innovation through the development of a high-value asset pipeline, including collaborations with leading partners such as Blackstone Life Sciences in GRIN Therapeutics. Today, we take another significant step with the acquisition of Catalyst Pharmaceuticals, which we believe will establish Angelini Pharma as a relevant global player in neurological Rare Diseases. Entering the U.S. market will allow us to acquire the scale and capabilities needed to continue this journey. Patient care remains at the heart of our vision. We continue to look ahead with determination, backed by a clear strategy and the drive to keep growing on a global scale. We are proud of a transaction that demonstrates, once again, the dynamism of the Italian pharmaceutical industry. “

Rich Daly, President and CEO of Catalyst, commented: “This is a pivotal and transformative moment for Catalyst, our team, and the patients we serve. By combining our unique capabilities in rare diseases with Angelini’s proven global reach, we will create a stronger, scalable, and robust rare disease platform to expand access to life-changing therapies worldwide. For shareholders, this transaction delivers immediate and certain cash value through a compelling premium. We are proud of the incredible foundation our team has built and are confident that together with Angelini, we can enhance patient support, accelerate innovation, and continue to drive sustainable long-term value for all stakeholders.” 

Transaction Terms

Under the terms of the agreement, a subsidiary of Angelini Pharma will merge with and into Catalyst, and, following the merger, Catalyst will survive as a wholly owned subsidiary of Angelini Pharma. Angelini Pharma expects to finance the acquisition with a combination of cash and debt. The acquisition is not subject to any financing condition.

The agreement has been unanimously approved by the Boards of Directors of both companies. The parties expect to close the acquisition in the third quarter of 2026, subject to approval by Catalyst stockholders, the receipt of required regulatory approvals, and satisfaction of other customary conditions. Due to the pendency of the transaction, Catalyst’s 2026 annual meeting of stockholders will be suspended.

Pending U.S. FIRDAPSE IP Litigation Resolved

Separately, Catalyst announced today that it has resolved the patent litigation it brought in response to an Abbreviated New Drug Application filed on behalf of Hetero USA, Inc, (together with its affiliated parties who are parties to the litigation, “Hetero”) seeking approval to market a generic version of FIRDAPSE® (amifampridine)10 mg tablets prior to expiration of the applicable Catalyst patents. In connection with the resolution of the patent litigation, Catalyst and its licensor SERB S.A. have entered into a Settlement Agreement with Hetero. As required by law, the companies will submit the confidential settlement agreement to the U.S. Federal Trade Commission and the U.S. Department of Justice for review. In accordance with the agreement, the parties will terminate all ongoing patent litigation between Catalyst/SERB and Hetero regarding FIRDAPSE patents pending in the U.S. District Court for the District of New Jersey. This settlement resolves all pending patent litigation relating to FIRDAPSE.

Advisors

Centerview Partners is serving as lead financial advisor, BNP Paribas and Morgan Stanley & Co. International plc. are acting as co-advisors to Angelini Pharma in connection with the acquisition, and Hogan Lovells and Gatti, Pavesi, Bianchi, Ludovici Studio Legale are serving as legal counsel to Angelini Pharma. BNP Paribas is acting as Sole Global Coordinator and Underwriter for the debt financing to Angelini Pharma. J.P. Morgan Securities LLC is serving as sole financial advisor to Catalyst, and Kirkland & Ellis LLP and Akerman LLP are serving as legal counsel to Catalyst.

About Angelini Pharma

Angelini Pharma is an international pharmaceutical company and part of the Angelini Industries Group. The company researches, develops, and commercializes health solutions with a particular focus on Brain Health, including mental health and epilepsy, and the Consumer market. Founded in Italy at the beginning of the twentieth century, Angelini Pharma operates directly in 20 countries, employing more than 3,000 people. Its products are commercialized in over 70 countries through strategic alliances with leading international pharmaceutical groups. For more information on Angelini Pharma, visit https://www.angelinipharma.com.

About Angelini Industries

Angelini Industries is a multinational group founded in Ancona in 1919 by Francesco Angelini. Today, Angelini Industries is a solid and diversified industrial group employing approximately 5,800 people and operating in 21 countries worldwide, with revenues of over 2 billion euros generated across the healthcare, industrial technology, and consumer goods sectors. A targeted growth investment strategy, a constant commitment to research and development, and an in-depth knowledge of markets and business sectors make Angelini Industries one of Italy’s leading companies in the sectors in which it operates. For more information, visit www.angeliniindustries.com.

About Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence, which remains the cornerstone of our commercial strategy, while continuously evaluating strategic opportunities to expand our global footprint. Catalyst, headquartered in Coral Gables, FL, has been recognized by Forbes as one of America’s Most Successful Company in 2023, 2024, and 2025, and on the 2025 Deloitte Technology Fast 500™ list as one of North America’s Fastest-Growing Companies. For more information, please visit Catalyst’s website at www.catalystpharma.com.

Important Information and Where to Find It

In connection with the proposed acquisition of Catalyst and Parent (the “Transaction”), Catalyst intends to file with the Securities and Exchange Commission (“SEC”) a proxy statement (the “Proxy Statement”), the definitive version of which will be sent or provided to Catalyst stockholders. Catalyst may also file other documents with the SEC regarding the proposed transaction. This document is not a substitute for the Proxy Statement or any other document which Catalyst may file with the SEC. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND RELATED MATTERS. Investors and security holders may obtain free copies of the Proxy Statement (when it is available) and other documents that are filed or will be filed with the SEC by Catalyst through the website maintained by the SEC at www.sec.gov or Catalyst’s website at https://ir.catalystpharma.com/financial-information/sec-filings/default.aspx.

No Offer or Solicitation

This communication is for information purposes only and is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation of any vote or approval in any jurisdiction, pursuant to the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.

Participants in the Solicitation

Catalyst, Angelini Pharma, and certain of their respective directors and executive officers may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Information regarding Catalyst’s directors and executive officers, including a description of their direct interests, by security holdings or otherwise, is contained in the “Directors, Executive Officers and Corporate Governance,” “Executive Compensation” and “Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters” sections of the Amended Annual Report on Form 10-K/A for the fiscal year ended December 31, 2025, of Catalyst, which was filed with the SEC on April 30, 2026 (the “Amended 2026 Annual Report”), and which will be contained in the Proxy Statement to be filed by Catalyst in connection with the proposed transaction. To the extent the holdings of Catalyst’s securities by Catalyst’s directors and executive officers have changed since the amounts set forth in Catalyst’s Amended 2026 Annual Report, such changes will be reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Change in Ownership on Form 4 filed with the SEC. Catalyst stockholders may obtain additional information regarding the direct and indirect interests of the participants in the solicitation of proxies in connection with the proposed transaction, including the interests of Catalyst directors and executive officers in the transaction, which may be different than those of Catalyst stockholders generally, by reading the Proxy Statement and any other relevant documents that are filed or will be filed with the SEC relating to the transaction. These documents (when available) may be obtained free of charge from the website maintained by the SEC at www.sec.gov and Catalyst’s website at https://ir.catalystpharma.com/financial-information/sec-filings/default.aspx.

Forward-Looking Statements

This Press Release contains certain “forward-looking statements” intended to qualify for the “safe harbor” from liability established by the Private Securities Litigation Reform Act of 1995, as amended, related to Catalyst, Angelini Pharma and the proposed acquisition of Catalyst by Angelini Pharma (the “Transaction”) that involve substantial risks and uncertainties. Forward-looking statements include any statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “goal,” “may,” “might,” “plan,” “predict,” “project,” “seek,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue” and similar expressions. In this press release, the forward-looking statements include statements about the parties’ ability to satisfy the conditions to the consummation of the Transaction; statements about the expected timetable for completing the Transaction; Catalyst’s plans, objectives, expectations and intentions; the financial condition, results of operations and business of Catalyst; Catalyst’s ability to commercialize its existing products and current and future product candidates; and the anticipated timing of closing of the Transaction. Forward-looking statements are subject to certain risks, uncertainties or other factors that are difficult to predict and could cause actual events or results to differ materially from those indicated in any such statements due to a number of risks and uncertainties. Those risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include, among other things: among other things: consummating the Transaction and financing in the anticipated timeframe, if at all; the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement; uncertainties as to the ability to obtain stockholder approval; the possibility that competing acquisition proposals will be made; the possibility that various closing conditions for the Transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the Transaction (or only grant approval subject to adverse conditions or limitations); the effects of the Transaction on relationships with employees, customers, suppliers, other business partners or governmental entities, including the risk that the Transaction adversely affects employee retention; the difficulty of predicting the timing or outcome of regulatory approvals or actions; the impact of competitive products and pricing; the risk that Angelini Pharma may not realize the potential benefits of the Transaction, including the possibility that the expected benefits from the proposed Transaction will not be realized or will not be realized within the expected time period and that Angelini Pharma and Catalyst will not be integrated successfully or that such integration may be more difficult, time-consuming or costly than expected; the risks related to disruption of management’s time from ongoing business operations as a result of the Transaction; risks that the Transaction disrupts current plans and operations; obtaining and maintaining adequate coverage and reimbursement for Catalyst’s products; changes in Catalyst’s business during the period between announcement and closing of the Transaction; any legal proceedings and/or regulatory actions that may be instituted related to the Transaction; other business effects, including the effects of industry, economic or political conditions outside of the companies’ control; costs and expenses related to the Transaction; actual or contingent liabilities; the effects of the Transaction (or the announcement thereof) on Catalyst’s stock price and/or operating results; and the other risks and uncertainties discussed under the heading “Risk Factors” in Catalyst’s periodic reports filed with the SEC, including its quarterly reports on Form 10 Q and annual reports on Form 10-K. These risks, as well as other risks associated with the Transaction, will be more fully discussed in the Proxy Statement to be filed with the SEC in connection with the Transaction. While the list of factors presented here is, and the list of factors presented in the Proxy Statement will be, considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. You should not place undue reliance on these statements. Actual results could differ materially from those anticipated in these forward-looking statements. All forward-looking statements are based on information currently available to Catalyst and Angelini Pharma, and, except as required by applicable law, Catalyst and Angelini Pharma disclaim any obligation to update the information contained in this Current Report on Form 8-K as new information becomes available. All forward-looking statements in this press release or made in connection therewith in writing or orally are qualified in their entirety by this cautionary statement.

Media Contacts

Angelini Pharma

Roberto Scrivo

Chief External Affairs Communication & Sustainability Officer

+39 348 454 6502

[email protected]

Chiara Antoniucci

Global External & Internal Communication Director

+39 347 713 3926

[email protected]

Federica Marcelli

Italy Media Communications Manager

+39 3383924138

[email protected]

Catalyst

Investors
Melissa Kendis, Catalyst Pharmaceuticals, Inc.
(305) 420-3200
[email protected]

Media
Jed Repko / Mahmoud Siddig
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449



Posted on

Kraft Heinz Commences Cash Tender Offer for Up To $1.1 Billion Aggregate Purchase Price of Certain of its Outstanding Notes

Kraft Heinz Commences Cash Tender Offer for Up To $1.1 Billion Aggregate Purchase Price of Certain of its Outstanding Notes

PITTSBURGH & CHICAGO–(BUSINESS WIRE)–
The Kraft Heinz Company (“Kraft Heinz”) (Nasdaq: KHC) announced today that Kraft Heinz Foods Company, its 100% owned subsidiary (the “Issuer”), has commenced an offer to purchase for cash (the “Tender Offer”) up to the maximum combined aggregate purchase price of $1,100,000,000, excluding accrued and unpaid interest (the “Maximum Tender Amount”), of its outstanding 4.375% Senior Notes due June 2046 and its 4.875% Senior Notes due October 2049 (collectively, the “Notes” and, each, a “Series” of Notes), from each registered holder of the Notes (the “Holders”). Subject to the Maximum Tender Amount, the amount of a Series of Notes that is purchased in the Tender Offer will be based on the Acceptance Priority Levels set forth in the table below. The Tender Offer is being made on the terms and subject to the conditions set forth in the offer to purchase dated May 7, 2026 (the “Offer to Purchase”). Capitalized terms used in this release but not otherwise defined have the meaning given in the Offer to Purchase.

CUSIP No. / ISIN

Title of

Security

Principal Amount Outstanding

Acceptance Priority Level

Reference Treasury

Security

Bloomberg Reference Page

Fixed Spread (bps)

Early Tender Premium(1)(2)

50077L AB2 / US50077LAB27

(144A): 50077L AA4 / US50077LAA44

(Reg S): U5009L AA8 / USU5009LAA80

4.375% Senior Notes due June

2046

$2,786,174,000

1

4.625%

U.S. Treasury due Feb. 15, 2046

FIT1

+100

$30

50077L AZ9 / US50077LAZ94

(144A): 50077L AY2 / US50077LAY20

(Reg S): U5009LAZ3 / USU5009LAZ32

4.875% Senior Notes due

October 2049

$1,450,000,000

2

4.625%

U.S. Treasury due Feb. 15, 2046

FIT1

+116

$30

_____________

(1)

The Total Consideration (as defined below) for each Series validly tendered prior to or at the applicable Early Tender Time (as defined below) and accepted for purchase is calculated using the applicable Fixed Spread (as defined below) and is inclusive of the applicable Early Tender Premium (as defined below).

(2)

Per $1,000 principal amount of Notes validly tendered and not validly withdrawn at or prior to the Early Tender Time and accepted for purchase (the “Early Tender Premium”).

Consummation of the Tender Offer and payment for the Notes accepted for purchase are subject to the satisfaction or waiver of certain conditions described in the Offer to Purchase, including among other things, the receipt of proceeds upon settlement of an offering of new senior unsecured notes on terms satisfactory to the Issuer (the “Financing Condition”). Subject to applicable law, the Issuer has reserved the right, in its sole discretion, to at any time (i) waive any and all conditions to the Tender Offer, including the satisfaction of Financing Condition, (ii) extend, terminate, or withdraw the Tender Offer, (iii) increase or waive the Maximum Tender Amount, with or without extending the Withdrawal Date (as defined below), or (iv) otherwise amend the Tender Offer in any respect.

The Tender Offer will expire at 5:00 p.m. New York City time, on June 5, 2026, unless extended with respect to a Series of Notes (such time and date, as they may be extended, the “Expiration Time”) or earlier terminated as described in the Offer to Purchase. Notes tendered at or prior to 5:00 p.m. New York City time, on May 20, 2026 (such date and time, as the same may be extended, the “Withdrawal Date”) may be validly withdrawn at any time at or prior to the Withdrawal Date, but not thereafter, except in certain limited circumstances where the Issuer determines that additional withdrawal rights are required by law. Holders are urged to read the Offer to Purchase carefully before making any decision with respect to the Tender Offer.

Holders who validly tender and do not validly withdraw their Notes at or prior to 5:00 p.m. New York City time, on May 20, 2026, unless extended with respect to any Series of Notes (such date and time, as the same may be extended, the “Early Tender Time”) or earlier terminated by the Issuer, will be eligible to receive the applicable Total Consideration, which includes the applicable Early Tender Premium as set forth in the table above. The applicable Total Consideration for each $1,000 principal amount of Notes validly tendered and accepted for purchase will be determined in the manner described in the Offer to Purchase by reference to the Fixed Spread for the applicable Series specified on the front cover of the Offer to Purchase over the applicable Reference Yield based on the bid-side price of the applicable Reference Treasury Security specified on the front cover of the Offer to Purchase, as calculated by the Dealer Managers (as defined below) at 10:00 a.m. New York City time, on May 21, 2026 (subject to certain exceptions set forth in the Offer to Purchase, such time and date, as the same may be extended the “Price Determination Date”). Holders who validly tender their Notes after the Early Tender Time and at or prior to the Expiration Time will be entitled to receive only the applicable Tender Offer Consideration, which is equal to the applicable Total Consideration minus the applicable Early Tender Premium.

For Notes validly tendered at or prior to the Early Tender Time, and not subsequently validly withdrawn and that are accepted for purchase, the Issuer has the option for settlement to occur on the Early Settlement Date, which is expected to be May 26, 2026, the third business day after the Early Tender Time. In the event the Issuer chooses to have an Early Settlement Date, settlement for Notes validly tendered after the Early Tender Time, but at or prior to the Expiration Time, is expected to occur on June 9, 2026, the second business day following the Expiration Time, unless extended.

In addition to the Total Consideration or the Tender Offer Consideration, as applicable, all Notes accepted for purchase pursuant to the Tender Offer will on the Early Settlement Date or the Final Settlement Date, as applicable, also receive accrued and unpaid interest in respect of such Notes from the most recent applicable interest payment date to, but excluding, the applicable Settlement Date.

Subject to the Maximum Tender Amount, the application of the Acceptance Priority Levels, and the other terms and conditions described in the Offer to Purchase, including the Financing Condition, the Issuer intends to accept for purchase all Notes validly tendered and not validly withdrawn at or prior to the Expiration Time. However, if the Tender Offer is fully subscribed as of the Early Tender Time, Holders who validly tender their Notes after the Early Tender Time but at or prior to the Expiration Time will not have any of their Notes accepted for purchase. Notes validly tendered and not validly withdrawn at or prior to the Early Tender Time will be accepted for purchase in priority to the Notes validly tendered after the Early Tender Time and at or prior to the Expiration Time, even if such Notes validly tendered after the Early Tender Time and at or prior to the Expiration Time have a higher Acceptance Priority Level than the Notes validly tendered and not validly withdrawn at or prior to the Early Tender Time. As a result, each Holder who validly tenders Notes pursuant to the Tender Offer may have a portion of its Notes returned to it, and the amount of Notes returned will depend on the level of participation of Holders in the Tender Offer. The Tender Offer may be subject to proration if the aggregate purchase price (excluding accrued and unpaid interest) of the Notes that are validly tendered and not validly withdrawn is greater than the Maximum Tender Amount. The Issuer reserves the right, subject to applicable law, but is under no obligation, to increase or waive the Maximum Tender Amount, in its sole discretion, with or without extending the Withdrawal Date. No assurance can be given that the Issuer will increase or waive the Maximum Tender Amount.

Kraft Heinz has engaged BofA Securities, Inc. (“BofA Securities”), Citigroup Global Markets Inc. (“Citigroup”), Deutsche Bank Securities Inc. (“Deutsche Bank Securities”) and Goldman Sachs & Co. LLC (“Goldman Sachs”) to act as dealer managers (collectively, the “Dealer Managers”) in connection with the Tender Offer and has appointed Global Bondholder Services Corporation to serve as the Tender Agent and Information Agent for the Tender Offer. Copies of the Offer to Purchase are available at https://www.gbsc-usa.com/kraftheinzcompany/ or by contacting Global Bondholder Services Corporation via telephone at (855) 654-2015 (toll free) or (212) 430-3774 (for banks and brokers). Questions regarding the terms of the Tender Offer should be directed to BofA Securities at (888) 292-0070 (toll-free) or (980) 387-3907 (collect); Citigroup at (800) 558-3745 (toll-free) or (212) 723-6106 (collect); Deutsche Bank Securities at (866) 627-0391 (toll-free) or (212) 250-2955 (collect); or Goldman Sachs at (800) 828-3182 (toll-free) or (212) 357-1452 (collect).

None of the Issuer, Kraft Heinz, their boards of directors or boards of managers, as applicable, the Dealer Managers, Global Bondholder Services Corporation, the Trustee for the Notes, or any of their respective affiliates, is making any recommendation as to whether Holders should tender any Notes in response to the Tender Offer. Holders must make their own decision as to whether to tender any of their Notes and, if so, the principal amounts of Notes to tender.

This press release is for informational purposes only and is not an offer to purchase, a solicitation of an offer to purchase, or a solicitation of consents with respect to any securities. This press release does not describe all the material terms of the Tender Offer, and no decision should be made by any Holder on the basis of this press release. The terms and conditions of the Tender Offer are described in the Offer to Purchase, and this press release must be read in conjunction with the Offer to Purchase. The Offer to Purchase contains important information that should be read carefully before any decision is made with respect to the Tender Offer. The Tender Offer is not being made in any jurisdiction in which, or to or from any person to or from whom, it is unlawful to make such offer or solicitation under applicable securities or blue sky laws. If any Holder is in any doubt as to the contents of this press release, or the Offer to Purchase, or the action it should take, the Holder should seek its own financial and legal advice, including in respect of any tax consequences, immediately from its stockbroker, bank manager, solicitor, accountant, or other independent financial, tax, or legal adviser. Any individual or company whose Notes are held on its behalf by a broker, dealer, bank, custodian, trust company, or other nominee must contact such entity if it wishes to tender such Notes pursuant to the Tender Offer.

ABOUT THE KRAFT HEINZ COMPANY

Kraft Heinz (Nasdaq: KHC) is one of the world’s largest food and beverage companies, withapproximately $25 billion in net sales in 2025 and a portfolio of iconic brands enjoyed by consumers in more than 40 countries. By investing in our capabilities and brands, including Heinz, Kraft, Philadelphia, Primal Kitchen, and Lunchables, we are unlocking the full power of our portfolio. We deliver high‑quality, great‑tasting, and affordable food for the consumers of today, while shaping the future of food.

Forward-Looking Statements

This press release contains certain statements that may be considered “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts and may be identified by words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “could,” “should,” “will,” “would,” and variations of such words and similar future or conditional expressions are intended to identify forward-looking statements. Examples of forward-looking statements include, but are not limited to, statements regarding the anticipated timing and completion of the Tender Offer; the anticipated satisfaction of conditions to the Tender Offer, including the expected timing, terms, and completion of a new senior unsecured notes offering to satisfy the Financing Condition and the expected use of net proceeds from such new senior unsecured notes offering to fund the purchase of Notes in the Tender Offer and to pay related fees and expenses; the expected aggregate principal amount of Notes to be purchased in the Tender Offer; and any other statements regarding the plans, expectations, or intentions with respect to the Tender Offer or the related financing.

These forward-looking statements reflect management’s current expectations, estimates and assumptions, and are not guarantees of future performance and are subject to a number of risks and uncertainties, many of which are difficult to predict and beyond Kraft Heinz’s control. Such risks, uncertainties, and other factors include, but are not limited to: Kraft Heinz’s ability to consummate the Tender Offer on the terms and conditions or the timeline described in the Offer to Purchase, or at all; the satisfaction or waiver of the conditions to the Tender Offer, including the Financing Condition; Kraft Heinz’s ability to consummate the proposed new senior unsecured notes offering on terms satisfactory to Kraft Heinz, in a timely manner, or at all, due to adverse changes in the corporate credit markets, prevailing interest rates, or general economic conditions; changes in laws, regulations, or regulatory interpretations that may affect Kraft Heinz’s ability to consummate the Tender Offer or the related financing; the aggregate principal amount of Notes of each series ultimately tendered and the level of participation of Holders in the Tender Offer; the timing of the settlement of the Tender Offer and the related financing; and volatility of capital markets and other macroeconomic factors. For additional information on other factors that could affect the Kraft Heinz’s forward-looking statements, see Kraft Heinz’s risk factors, as they may be amended from time to time, set forth in its filings with the Securities and Exchange Commission (the “SEC”). Any forward-looking statement made in this press release speaks only as of the date hereof and is expressly qualified in its entirety by the cautionary statements set forth herein and the risk factors and other cautionary statements contained in Kraft Heinz’s filings with the SEC. Kraft Heinz disclaims and does not undertake any obligation to update, revise, or withdraw any forward-looking statement in this press release, except as required by applicable law or regulation. Readers are cautioned not to place undue reliance on any forward-looking statements.

Kraft Heinz Media Team (media)

[email protected]

Anne-Marie Megela (investors)

[email protected]

KEYWORDS: Illinois Pennsylvania United States North America

INDUSTRY KEYWORDS: Restaurant/Bar Food/Beverage Other Retail Retail Supermarket

MEDIA:

Logo
Logo
Posted on

Apollo Funds Complete Acquisition of Prosol Group

NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) — Apollo (NYSE: APO) today announced that Apollo-managed funds (the “Apollo Funds”) have completed the previously announced acquisition of a majority stake in Prosol Group (“Prosol” or the “Company”), the multi-specialist in fresh food businesses and food retail in France, from Ardian, a global private investment firm. Prosol’s existing minority shareholders and management team have reinvested alongside the Apollo Funds.

Founded in 1992, Prosol has differentiated itself by building a proprietary, vertically integrated supply chain, sourcing fresh, quality products resulting in a highly loyal and fast-growing customer base. Prosol operates and/or supplies nearly 450 stores across France under two main banners, Grand Frais and fresh. Chief Executive Officer Jean-Paul Mochet will continue to lead the Company as it sets out to achieve its long-term growth ambitions, expanding Prosol’s distinctive retail concept to more customers.

UBS AG served as lead financial advisor to the Apollo Funds, while Royal Bank of Canada and Lazard also served as financial advisors. Sidley Austin LLP, Paul, Weiss, Rifkind, Wharton & Garrison LLP and Cleary Gottlieb Steen & Hamilton LLP served as legal counsel on the transaction.

About Apollo

Apollo is a high-growth, global alternative asset manager. In our asset management business, we seek to provide our clients excess return at every point along the risk-reward spectrum from investment grade credit to private equity. For more than three decades, our investing expertise across our fully integrated platform has served the financial return needs of our clients and provided businesses with innovative capital solutions for growth. Through Athene, our retirement services business, we specialize in helping clients achieve financial security by providing a suite of retirement savings products and acting as a solutions provider to institutions. Our patient, creative, and knowledgeable approach to investing aligns our clients, businesses we invest in, our employees, and the communities we impact, to expand opportunity and achieve positive outcomes. As of March 31, 2026, Apollo had approximately $1.03 trillion of assets under management.

About Prosol

A leading player in specialised food retail in France, PROSOL has been developing an integrated, fresh-food-focused model for more than 30 years. By exercising full control over the value chain — from agricultural sourcing to distribution — the company ensures freshness, quality and traceability, in support of better eating for all.

Designed as a true infrastructure dedicated to taste, PROSOL’s model is built on long-term partnerships with carefully selected producers, in-house expertise in product enhancement and maturation, proprietary production facilities, and a dedicated, high-performance logistics network.

With nearly 450 points of sale, PROSOL operates a portfolio of complementary retail brands, including Grand Frais, fresh., La Boulangerie du Marché, mon-marché.fr, BioFrais, and Banco Fresco in Italy. Within Grand Frais stores, the company directly operates the fruit and vegetable, fish, dairy and cheese departments, as well as butchery departments in the Paris region and Eastern France.

Contacts

Noah Gunn
Global Head of Investor Relations
Apollo Global Management, Inc.
(212) 822-0540
[email protected]

Joanna Rose
Global Head of Corporate Communications
Apollo Global Management, Inc.
(212) 822-0491
[email protected] / [email protected]



Posted on

Criteo Selects Navan to Modernize Global Travel Management

Criteo Selects Navan to Modernize Global Travel Management

Global commerce intelligence platform delivers high employee satisfaction with Navan

PALO ALTO, Calif.–(BUSINESS WIRE)–Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced that it has been selected by Criteo, the global commerce intelligence platform, to modernize its global travel program.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507251188/en/

Global commerce intelligence platform delivers high employee satisfaction with Navan

Global commerce intelligence platform delivers high employee satisfaction with Navan

Criteo set out to provide its global workforce with an easy-to-use travel booking experience that brought visibility and control to its travel spending. Prioritizing operational excellence and employee experience, Criteo selected Navan because of its extensive inventory, unified travel and payments platform, and global expertise in sustainability reporting.

“We wanted to give our teams a travel tool that’s as easy to use as the apps they use in their personal lives,” said Sarah Glickman, Chief Financial Officer at Criteo. “Our goal with Navan was to improve the user experience for both travelers and managers, and to bring a richer breadth of travel content directly into a single platform.”

Following a rapid two-month rollout across 21 countries, Navan’s AI-powered platform has delivered measurable impact across Criteo’s global operations:

  • High employee adoption: A 91% satisfaction score shows that employees enjoy using the new system.
  • Operational speed: Navan’s support teams handle 85% of traveler interactions in less than 60 seconds, ensuring employees are never left stranded.
  • Sustainability tracking: The platform shows CO2 emissions at checkout, helping Criteo employees more effectively track carbon budgets.

“Criteo is a fast-moving global business, and they needed a travel platform that could keep up with their growth,” said Zahir Abdelouhab, SVP, EMEA, Navan. “We’re proud to help them to replace legacy tools with an AI travel system that is faster, simpler, and more intuitive for their employees.”

Criteo joins a growing list of enterprise organizations that have recently switched to Navan, including industry leaders from the media sector, including Yahoo and Axel Springer.

About Navan

Navan is the global AI-powered business travel and expense platform that makes travel easy for frequent travelers. From finding flights and hotels, to automating expense reconciliation, with 24/7 support along the way, Navan delivers an intuitive experience travelers love and finance teams rely on. See how Navan customers benefit and learn more at navan.com.

Navan Press

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Technology Other Travel Transportation Software Destinations Artificial Intelligence Travel

MEDIA:

Photo
Photo
Global commerce intelligence platform delivers high employee satisfaction with Navan
Posted on

LMR Naturals to Showcase Leadership in Natural Ingredients at SIMPPAR, the International Exhibition of Raw Materials for Perfumery

LMR Naturals to Showcase Leadership in Natural Ingredients at SIMPPAR, the International Exhibition of Raw Materials for Perfumery

Advancing sustainable, high-quality naturals through end‑to‑end stewardship

GRASSE, France–(BUSINESS WIRE)–LMR Naturals by IFF — a global leader in natural ingredients for perfumery, cosmetics and flavors — will debut its latest innovations at the International Exhibition of Raw Materials for Perfumery (SIMPPAR), May 26–27 in Grasse. During the industry event, IFF will unveil new additions to its LMR Hearts collection, highlighting its naturals expertise and pioneering science.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260506065669/en/

Bernard Blerot, VP R&D Naturals at IFF, smelling geranium in a botanical research laboratory.

Bernard Blerot, VP R&D Naturals at IFF, smelling geranium in a botanical research laboratory.

“Responsible innovation has always been central to LMR,” said Bertrand de Préville, general manager of LMR. “Our strength lies in our ability to master the full range of natural technologies to support perfumers’ creativity. We’re connecting nature, science and creation to drive sustainable growth and deliver added value to our customers at global scale.”

Four New LMR Hearts Introduced at SIMPPAR

LMR Naturals’ new LMR Hearts, each developed through long‑term sourcing partnerships, sustainable agricultural practices and precision molecular distillation andfractionation at LMR’s Grasse site include:

  • Lavandin Heart France, withastrong coumarin profile for a more gourmand note
  • Armoise Heart Morocco, which isricher in thujones for a fresher, more diffusive impact
  • Ylang Heart Madagascar, offeringa unique “extra grade”, creamy and solar olfactive profile
  • Geranium Heart Egypt, featuring a fruity-lychee profile without conventional minty aspects

“These new Hearts illustrate how science and sourcing expertise can elevate natural ingredients,” said Bernard Blerot, VP R&D Naturals at IFF. “They provide greater purity and focus while maintaining the integrity of the natural material and demonstrate our team’s scientific stewardship.”

Natural Ingredients Innovation

The four LMR Hearts launched at SIMPPAR follow several natural ingredient innovations introduced earlier this year, including:

  • Tonka Bean CO₂ Absolute, produced using renewable supercritical CO₂ extraction at LMR’s Aumont‑Aubrac facility in France
  • Osmanthus Absolute Fruity China, a fruit‑forward interpretation developed as a captive natural for IFF perfumers
  • Pulpextract™ Passion Fruit and Raspberry, two new fruit ingredients offering vivid, juicy profiles exclusively for IFF perfumers

Each new natural ingredient responds to sustained consumer interest in fruity and gourmand fragrance notes, which IFF insights show make up a significant and enduring share of women’s fragrances. LMR strives to continuously expand the perfumer’s palette with naturals that combine innovation, sustainability and olfactive expression.

These launches support IFF’s 25‑year investment in LMR and sustainable, natural materials, embedding pioneering science — from seed and cultivation to harvesting and extraction — in perfumers’ creativity at scale. In late May, IFF will further strengthen this integrated ecosystem with the inauguration of the Domaine des Naturals LMR in Grasse, a dedicated experimental field for raw materials that underscores its long‑term commitment to the future of naturals and innovation.

LMR Naturals’ integrated natural ingredients platform combines long‑term sourcing partnerships, agronomy‑led sustainability programs and internally operated extraction technologies — including molecular distillation, fractionation, CO₂ extraction and more. By operating these technologies on its own sites, LMR Naturals and its internal team of experts can focus on the most desirable olfactive molecules as selected by perfumers. With this approach, LMR Naturals delivers traceable, sustainable and performance‑driven natural ingredients for fine fragrance and other applications.

About LMR Naturals by IFF

Founded in 1983 by Monique Rémy and acquired by IFF in 2000, LMR Naturals is a trademarked capability within IFF dedicated to the development of high‑quality, innovative and sustainably sourced natural ingredients. LMR Naturals supports perfumers worldwide with a broad portfolio of naturals across fine fragrance, beauty, personal care, home care and flavorists with taste applications.

For more information, visit https://www.iff.com/scent/lmr-naturals/.

Welcome to IFF

At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in taste, scent, food ingredients, health and biosciences, we’re innovating for the future. Every day, we deliver groundbreaking, sustainable solutions that elevate products people love — advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook.

© 2026 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved

Judith Gross, VP, Communications & Branding

Department: Scent

Email: [email protected]

KEYWORDS: France Europe

INDUSTRY KEYWORDS: Technology Manufacturing Food/Beverage Other Science Other Technology Cosmetics Retail Environment Science Sustainability Chemicals/Plastics

MEDIA:

Photo
Photo
Bernard Blerot, VP R&D Naturals at IFF, smelling geranium in a botanical research laboratory.
Logo
Logo
Posted on

Accenture Partners with the WTA to Help Build the Future of Women’s Tennis

Accenture Partners with the WTA to Help Build the Future of Women’s Tennis

Reinventing the ‘WTA Player Zone’ experience for athletes through technology, data, and AI

ROME–(BUSINESS WIRE)–
Accenture (NYSE: ACN) and the WTA (Women’s Tennis Association) have announced a new, multi-year partnership, focused on enhancing the player experience and helping shape the future of women’s tennis. The collaboration will fuse Accenture’s leadership in technology and AI enablement with the WTA’s commitment to excellence as a modern, athlete-first governing body.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260506788348/en/

Mauro Macchi, Accenture EMEA CEO, alongside Marina Storti, CEO WTA Ventures at the 2026 Italian Open, following partnership agreement

Mauro Macchi, Accenture EMEA CEO, alongside Marina Storti, CEO WTA Ventures at the 2026 Italian Open, following partnership agreement

As the Official Business and Technology Consulting Partner of the WTA, Accenture will work at the heart of the organization to modernize its digital ecosystem, introducing new levels of intelligence, connectivity, and data-driven insight to the WTA Tour Driven by Mercedes-Benz.

As part of the WTA’s ongoing efforts to enhance its support for its world-class players, an initial focus of the partnership will be to transform the WTA Player Zone – the central digital platform for every athlete on the tour – turning it into a seamless, data-driven and intuitive hub. By applying advanced technologies, including AI, the collaboration aims to streamline athletes’ interactions with WTA’s digital platforms, improving access to critical information, and enabling players to focus more fully on performance while the platform works seamlessly behind the scenes.

This work reflects a shared ambition to modernize the infrastructure behind women’s tennis while strengthening how the sport operates and grows at a global scale. By starting with the athlete experience, the partnership creates a foundation for continued innovation and growth across the WTA tour which will ultimately broaden in scope to engage new audiences and deepen live event experiences.

Mauro Macchi, CEO of Accenture in EMEA said: “Women’s tennis is already one of the most popular and commercially successful sports globally and we believe its future will be shaped by what we build. This ethos is at the heart of our partnership with the WTA where we look forward to combining technology, data and AI to reinvent the athlete experience and help drive the continued growth of the game around the world.”

The WTA operates one of the most global tours in sport, with more than 50 tournaments across 26 countries and territories, and a growing international fan base. A core part of the WTA’s mission is continuing to strengthen its support for players: providing the best stage on which to perform, supporting health and wellbeing, offering comprehensive maternity benefits, and breaking boundaries for athlete compensation. Through this partnership, Accenture will support the WTA in scaling its operations, strengthening its digital foundations, and unlocking new opportunities for players, fans and partners alike.

“We are proud to partner with Accenture as we continue to grow the WTA as the stage where women’s tennis shines,” said Marina Storti, CEO of WTA Ventures, the commercial arm of the WTA. “This collaboration is about more than just technology; it’s about advancing how we support our athletes by delivering a connected and efficient digital experience – while continuing our journey to grow women’s tennis globally.”

In addition to technology transformation, the partnership will include joint storytelling and content development to highlight the impact of the work and the broader momentum behind women’s sport. This announcement builds on Accenture’s growing portfolio of business-led partnerships across global sport – reinventing the future of sport through technology, data and AI to help organizations innovate, enhance experiences and unlock new sources of value.

The partnership with Accenture continues the WTA’s strong growth momentum, building on the recent launch of a long-term partnership with Mercedes-Benz, growing engagement from fans worldwide, the introduction of a bold new brand identity, and the award of the biggest-ever prize money payout in the history of both professional tennis tours and women’s sport (awarded to Elena Rybakina, singles champion at the 2025 WTA Finals Riyadh presented by PIF).

About Accenture

Accenture is a leading solutions and services company that helps the world’s leading enterprises reinvent by building their digital core and unleashing the power of AI to create value at speed across the enterprise, bringing together the talent of our approximately 786,000 people, our proprietary assets and platforms, and deep ecosystem relationships. Our strategy is to be the reinvention partner of choice for our clients and to be the most client-focused, AI-enabled, great place to work in the world. Through our Reinvention Services we bring together our capabilities across strategy, consulting, technology, operations, Song and Industry X with our deep industry expertise to create and deliver solutions and services for our clients. Our purpose is to deliver on the promise of technology and human ingenuity, and we measure our success by the 360° value we create for all our stakeholders. Visit us at accenture.com.

About the WTA

The WTA is the original game-changer for women’s sport. Founded in 1973 by the visionary Billie Jean King, the WTA was created to build equal opportunities for women in tennis, and we’ve been breaking boundaries ever since. Today we’re the powerhouse of women’s professional sports, uniting athletes in fearless competition and bringing people together through the love of tennis. The WTA Tour shares the thrill of every serve, rally and match point with an audience of more than one billion around the world. Players compete for PIF WTA ranking points in tournament arenas on six continents before the season hits its peak at the WTA Finals, where the best singles and doubles superstars battle to be crowned as year-end champions. Our ambitions go well beyond the court. We are champions for our incredible athletes and drivers of change through advocacy and action for women’s health and empowerment across the globe.

WTA Ventures, the commercial arm of the WTA, has a mission to fuel the growth of professional women’s tennis. Established in partnership with CVC Capital Partners in 2023, it aims to further elevate the profile of women’s tennis, improve the product for fans and accelerate commercial growth for the benefit of players, tournaments and everyone involved in the sport.

Copyright © 2026 Accenture. All rights reserved. Accenture and its logo are registered trademarks of Accenture.

Andy Rowlands

Accenture

+44 7952 594784

[email protected]

Chinedu Udezue

Accenture

+44 208 396 3674

[email protected]

Abi Hallworth

WTA

[email protected]

KEYWORDS: Italy Europe

INDUSTRY KEYWORDS: Data Management Sports Technology Software Networks Tennis Artificial Intelligence

MEDIA:

Photo
Photo
Mauro Macchi, Accenture EMEA CEO, alongside Marina Storti, CEO WTA Ventures at the 2026 Italian Open, following partnership agreement
Photo
Photo
Accenture and the WTA (Women’s Tennis Association) have announced a new, multi-year partnership, focused on enhancing the player experience and helping shape the future of women’s tennis.
Posted on

Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Hetero Labs Ltd.

As Part of the Settlement, Hetero Labs Ltd. Receives a License to Market Generic FIRDAPSE Beginning in January 2035

Catalyst has No Other FIRDAPSE Patent Litigation Pending

CORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that the Company and its licensor SERB S.A. (“SERB”) have entered into a Settlement Agreement (“Agreement”) with Hetero Labs Ltd., Hetero USA, Grace Consulting Services, Inc., and Annora Pharma Private Limited (collectively, Hetero). This Agreement resolves the patent litigation brought by Catalyst and SERB in response to Hetero’s Abbreviated New Drug Application (“ANDA”) seeking approval to market a generic version of FIRDAPSE® (amifampridine) 10 mg tablets prior to expiration of the applicable patents.

Pursuant to the terms of the Agreement, Hetero will not market its generic version of FIRDAPSE in the United States any earlier than a specified date in January 2035, if approved by the U.S. Food and Drug Administration, unless certain limited circumstances customarily included in these types of agreements occur. In accordance with the Agreement, the parties will terminate all ongoing patent litigation between Catalyst/SERB and Hetero regarding FIRDAPSE patents pending in the U.S. District Court for the District of New Jersey prior to the scheduled trial commencement on May 18, 2026. Catalyst previously settled similar litigation regarding ANDA applications for FIRDAPSE with Lupin Pharmaceuticals, Teva Pharmaceuticals, and Inventia Healthcare Limited. This settlement resolves all pending patent litigation relating to FIRDAPSE.

As required by law, the companies will submit the confidential settlement agreement to the U.S. Federal Trade Commission and the U.S. Department of Justice for review.

About Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence, which remains the cornerstone of our commercial strategy, while continuously evaluating strategic opportunities to expand our global footprint. Catalyst, headquartered in Coral Gables, Fla., was recognized on the Forbes 2025 list as one of America’s Most Successful Mid-Cap Companies and on the 2024 Deloitte Technology Fast 500™ list as one of North America’s Fastest-Growing Companies.

For more information, please visit Catalyst’s website at www.catalystpharma.com.

Forward-Looking Statements

This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst’s actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst’s Annual Report on Form 10-K for the fiscal year 2025 and its other filings with the U.S. Securities and Exchange Commission (“SEC”), could adversely affect Catalyst. Copies of Catalyst’s filings with the SEC are available from the SEC, may be found on Catalyst’s website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.

Source: Catalyst Pharmaceuticals, Inc.



Investor Contact
Melissa Kendis, Catalyst Pharmaceuticals, Inc.
(305) 420-3200
[email protected]

Media Contact
Jed Repko / Mahmoud Siddig
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449

Posted on

Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease

  • The Boards of Directors of Angelini Pharma and Catalyst Pharmaceuticals have unanimously approved the acquisition of Catalyst Pharmaceuticals at 31.50 USD per share in cash, for a total consideration of approximately 4.1 billion USD, representing a premium of 28% to the 30-day volume-weighted average trading price as of April 22, 2026
  • The transaction marks Angelini Pharma’s entry into the U.S. market, reinforcing its long-term commitment to Brain Health and its dedication to people living with Rare Diseases
  • Closing is expected in the third quarter of 2026

ROME and CORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) — Angelini Pharma S.p.A. (“Angelini Pharma”), an international pharmaceutical company and part of the Angelini Industries Group, and Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that they have entered into a definitive agreement pursuant to which Angelini Pharma has agreed to acquire all outstanding shares of Catalystfor 31.50 USD per share in cash, for a total equity value of approximately 4.1 billion USD (equivalent to 3.5 billion euros) which represents a 21% premium to Catalyst’s unaffected closing share price on April 22, 2026, the last trading day before market signs that the transaction had become public information, as well as a 28% premium to the 30-day volume-weighted average trading price to that unaffected date. The transaction has been unanimously approved by the Boards of Directors of both companies and is expected to close in the third quarter of 2026.

This acquisition marks a pivotal moment in the Angelini Group’s history — a group with over 100 years of history, chaired by Thea Paola Angelini, a fourth-generation member of the Angelini family — led by Sergio Marullo di Condojanni, Chief Executive Officer of Angelini Pharma.

The transaction will be carried out with the participation of Blackstone funds and select international partners, and will be financed with the support of BNP Paribas, acting as Sole Global Coordinator and Underwriter of the financing package.

Founded in 2002 and listed on Nasdaq since 2006, Catalyst has built a robust portfolio of products focused on the treatment of rare neuromuscular and neurological diseases: FIRDAPSE® (amifampridine), the only evidence-based treatment approved by the U.S. Food and Drug Administration (FDA) for Lambert-Eaton myasthenic syndrome (LEMS) in patients aged six and above; AGAMREE® (vamorolone) a novel corticosteroid approved by the FDA in 2023 for the treatment of Duchenne Muscular Dystrophy (DMD) in patients aged 2 and above; and FYCOMPA® (perampanel), an antiepileptic drug approved for the treatment of partial-onset seizures and primary generalised tonic-clonic seizures, the U.S. rights to which were acquired from Eisai in 2023.

Following completion of the acquisition, Angelini Pharma intends to integrate Catalyst’s portfolio and exceptional commercial infrastructure with its own expertise and products in Brain Health to develop a next-generation therapeutic platform in Rare Diseases. This transaction reinforces the commitment Angelini Pharma has built over recent years through products such as Ontozry® and high-profile scientific collaborations. Catalyst’s portfolio is expected to significantly strengthen the company’s strategic objectives, growing its presence in the U.S. as part of a balanced strategy that aims to develop the North American market while continuing to strengthen its core business in Europe. Angelini Pharma’s continued industrial presence in Italy will remain a strategic asset as a valuable production and scientific center within the combined company’s global operations.

Sergio Marullo di Condojanni, CEO of Angelini Pharma, commented: “Five years ago, we embarked on a profound transformation of Angelini Pharma — organizational, scientific and strategic — with the ambition to build a company capable of competing at the highest global level. On one hand, we continued to invest in our traditional portfolio; on the other, we chose to focus on central nervous system disorders, with the goal of addressing an unmet medical need that is, unfortunately, growing significantly. We invested in innovation through the development of a high-value asset pipeline, including collaborations with leading partners such as Blackstone Life Sciences in GRIN Therapeutics. Today, we take another significant step with the acquisition of Catalyst Pharmaceuticals, which we believe will establish Angelini Pharma as a relevant global player in neurological Rare Diseases. Entering the U.S. market will allow us to acquire the scale and capabilities needed to continue this journey. Patient care remains at the heart of our vision. We continue to look ahead with determination, backed by a clear strategy and the drive to keep growing on a global scale. We are proud of a transaction that demonstrates, once again, the dynamism of the Italian pharmaceutical industry.” 

Rich Daly, President and CEO of Catalyst, commented: “This is a pivotal and transformative moment for Catalyst, our team, and the patients we serve. By combining our unique capabilities in rare diseases with Angelini’s proven global reach, we will create a stronger, scalable, and robust rare disease platform to expand access to life-changing therapies worldwide. For shareholders, this transaction delivers immediate and certain cash value through a compelling premium. We are proud of the incredible foundation our team has built and are confident that together with Angelini, we can enhance patient support, accelerate innovation, and continue to drive sustainable long-term value for all stakeholders.” 

Media Contacts

Angelini Pharma

Roberto Scrivo
Chief External Affairs Communication & Sustainability Officer
+39 348 454 6502
[email protected] 

Chiara Antoniucci
Global External & Internal Communication Director
+39 347 713 3926
[email protected]

Federica Marcelli
Italy Media Communications Manager
+39 3383924138
[email protected]

Media
Jemini Sedani
Real Chemistry, Group Director, Media & Engagement
+44 (0)7940 594788
[email protected] 

Catalyst

Investors
Melissa Kendis, Catalyst Pharmaceuticals, Inc.
(305) 420-3200
[email protected]

Media
Jed Repko / Mahmoud Siddig
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449



Posted on

CMB.TECH announces Q1 2026 results on 19/05/2026

ANTWERP, Belgium, 7 May 2026 – CMB.TECH NV 
(NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO)
(“CMBT”, “CMB.TECH” or “the Company”) will release its first quarter 2026 earnings prior to market opening on Tuesday 19 May 2026 and will host a conference call at 8 a.m. EST / 2 p.m. CET to discuss the results for the quarter.

The call will be a webcast with an accompanying slideshow. You can find the details of this conference call below and on the “Investor Relations” page of the website. The presentation, recording & transcript will also be available on this page.

Webcast Information  
Event Type:  Video conference call with slide presentation
Event Date: 19 May 2026
Event Time: 8 a.m. EST / 2 p.m. CET
Event Title:  “Q1 2026 Earnings Conference Call”
Event Site/URL:   https://events.teams.microsoft.com/event/9600de65-6747-468b-bb10-eb435b6a1780@d0b2b045-83aa-4027-8cf2-ea360b91d5e4

To attend this conference call, please register via the following link.

Telephone participants who are unable to pre-register may dial in to the respective number of their location (to be found here). The Phone conference ID is the following: 266 848 625#


Announcement Q1 2026 results – 19 May 2026

About CMB.TECH

CMB.TECH (all capitals) is one of the largest listed, diversified and future-proof maritime groups in the world with a combined fleet of about 250 vessels: dry bulk vessels, crude oil tankers, chemical tankers, container vessels and offshore energy vessels. CMB.TECH also offers hydrogen and ammonia fuel to customers, through own production or third-party producers.

CMB.TECH is headquartered in Antwerp, Belgium, and has offices across Europe, Asia and Africa.

CMB.TECH is listed on Euronext Brussels and the NYSE under the ticker symbol “CMBT” and on Euronext Oslo Børs under the ticker symbol “CMBTO”.

More information can be found at https://cmb.tech

Forward-Looking Statements

Matters discussed in this press release may constitute forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbour protections for forward-looking statements in order to encourage companies to provide prospective information about their business. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts. The Company desires to take advantage of the safe harbour provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbour legislation. The words “believe”, “anticipate”, “intends”, “estimate”, “forecast”, “project”, “plan”, “potential”, “may”, “should”, “expect”, “pending” and similar expressions identify forward-looking statements.

The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, our management’s examination of historical operating trends, data contained in our records and other data available from third parties. Although we believe that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond our control, we cannot assure you that we will achieve or accomplish these expectations, beliefs or projections.

In addition to these important factors, other important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include the failure of counterparties to fully perform their contracts with us, the strength of world economies and currencies, general market conditions, including fluctuations in charter rates and vessel values, changes in demand for tanker vessel capacity, changes in our operating expenses, including bunker prices, dry-docking and insurance costs, the market for our vessels, availability of financing and refinancing, charter counterparty performance, ability to obtain financing and comply with covenants in such financing arrangements, changes in governmental rules and regulations or actions taken by regulatory authorities, potential liability from pending or future litigation, general domestic and international political conditions, potential disruption of shipping routes due to accidents or political events, vessels breakdowns and instances of off-hires and other factors. Please see our filings with the United States Securities and Exchange Commission for a more complete discussion of these and other risks and uncertainties.

This information is published in accordance with the requirements of the Continuing Obligations on Euronext Oslo Børs


Contact

CMB.TECH
Katrien Hennin
Head of Marketing and Communications
+32 499 39 34 70
[email protected]

Joris Daman
Head of Investor Relations
Tel: +32 498 61 71 11
[email protected]

Attachment